Newsletter Tool

Featured Story

On a roll, Moderna taps Thermo Fisher for fill-finish duties and Lonza for booster shot manufacturing

By Noah Higgins-Dunn

Moderna has tasked Thermo Fisher Scientific with fill-finish, labeling and packaging duties for its mRNA COVID-19 vaccine at Thermo Fisher’s commercial manufacturing site in Greenville, North Carolina. Meanwhile, Swiss CDMO Lonza will also build a new line at a site in the Netherlands to help produce booster shots.

NRx hopes 'guided missile' COVID-19 antiviral will get FDA clearance on 2nd attempt

By Kyle LaHucik

The FDA told NRx Pharmaceuticals to try again in September when they attempted to obtain authorization for a COVID-19 therapy. Now, the biotech thinks they have the data they need to finally get the nod. Radnor, Pennsylvania-based NRx filed for emergency use authorization yesterday with the FDA for aviptadil-acetate, or Zyesami, to be used in COVID-19 patients with respiratory failure.

Samsung adds mRNA vaccine substance capacity, eying a one-stop site to make Moderna's COVID-19 shot

By Kevin Dunleavy

South Korea CDMO Samsung Biologics said it will add mRNA vaccine substance manufacturing capability, allowing it to fully produce COVID-19 shots. Samsung already had a fill-finish agreement in place to produce Moderna's vaccine.

Pharma drug naming experts applaud WHO's choice of Greek alphabet for COVID-19 variants

By Beth Snyder Bulik

What’s in a COVID-19 variant name? Thanks to the World Health Organization, Greek letters. The global health organization's newly announced naming system uses the Greek alphabet in a standardized convention pharma drug naming experts agreed makes sense.

COVID-19 tracker: U.K. negotiates with AZ for 'beta' variant shots; Israel finds probable link between Pfizer vaccine, myocarditis

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

AstraZeneca is in talks with the British government to supply vaccine doses tailored to the "beta" variant of the coronavirus first identified in South Africa. Officials in Israel said there was a probable link between Pfizer's shot and rare cases of myocarditis. And more headlines.

Cleveland Clinic posts $61M profit in Q1 thanks to strong patient service revenue

By Robert King

Cleveland Clinic posted a $61 million profit in the first quarter thanks to strong patient service revenue, but still expects to face cost pressures this year due to COVID-19.

COVID-19 Tracker